Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
This study has been completed.
First Received: March 25, 2005   Last Updated: July 29, 2009   History of Changes
Sponsor: Genzyme
Information provided by: Genzyme
ClinicalTrials.gov Identifier: NCT00106509
  Purpose

Approximately 520 patients will be entered into this study taking place throughout the US and Canada. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C. difficile-associated diarrhea (CDAD) and lowering the risk of repeat episodes of CDAD. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 6 weeks.


Condition Intervention Phase
Clostridium Enterocolitis
Pseudomembranous Colitis
Drug: tolevamer potassium-sodium (GT267-004)
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea

Resource links provided by NLM:


Further study details as provided by Genzyme:

Primary Outcome Measures:
  • Resolution of diarrhea

Secondary Outcome Measures:
  • Time to resolution of diarrhea
  • Recurrence rate
  • Number of stools
  • Average stool consistency
  • Treatment success

Estimated Enrollment: 520
Study Start Date: March 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age
  • The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea
  • Less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for CDAD
  • Baseline serum potassium > 3.0 mmol (meq)/L
  • Patient considered sufficiently stable clinically to likely complete a 6 week study period
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00106509

  Hide Study Locations
Locations
United States, Arizona
Phoenix, Arizona, United States, 85006
Phoenix, Arizona, United States, 85012
United States, Arkansas
Rogers, Arkansas, United States, 72756
United States, California
Burbank, California, United States, 91505
Modesto, California, United States, 95350
Los Angeles, California, United States, 90073
Los Angeles, California, United States, 90089
Newport Beach, California, United States, 92663
Sacramento, California, United States, 95817
San Diego, California, United States, 92103
Los Angeles, California, United States, 90095
United States, Colorado
Denver, Colorado, United States, 80218-1191
Denver, Colorado, United States, 80210
Denver, Colorado, United States, 80262
Denver, Colorado, United States, 80204
United States, Delaware
Newark, Delaware, United States, 19718
United States, Florida
Bay Pines, Florida, United States, 33744
Jacksonville, Florida, United States, 32207
Zephyrhills, Florida, United States, 33542
Tampa, Florida, United States, 33607
Brooksville, Florida, United States, 34613
Brandon, Florida, United States, 33511
United States, Georgia
Atlanta, Georgia, United States, 30309
Ft. Gordon, Georgia, United States, 30905
Savannah, Georgia, United States, 31405
United States, Hawaii
Honolulu, Hawaii, United States, 96813
Honolulu, Hawaii, United States, 96813
United States, Illinois
Maywood, Illinois, United States, 60153
Chicago, Illinois, United States, 60634
North Chicago, Illinois, United States, 60064
Hines, Illinois, United States, 60141
Decatur, Illinois, United States, 62526
United States, Indiana
Lafayette, Indiana, United States, 47904
Muncie, Indiana, United States, 47303
Anderson, Indiana, United States, 46011
Indianapolis, Indiana, United States, 46202
United States, Iowa
Des Moines, Iowa, United States, 50302
Clive, Iowa, United States, 50325
Des Moines, Iowa, United States, 50309
Dubuque, Iowa, United States, 52002
Iowa City, Iowa, United States, 52242
United States, Kentucky
Louisville, Kentucky, United States, 40202
Louisville, Kentucky, United States, 40206-1499
Bowling Green, Kentucky, United States, 42101
United States, Louisiana
New Orleans, Louisiana, United States, 70115
New Orleans, Louisiana, United States, 70121
United States, Maryland
Hagerstown, Maryland, United States, 21740
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Worcester, Massachusetts, United States, 01608-1320
Boston, Massachusetts, United States, 02114
Boston, Massachusetts, United States, 02115
Worcester, Massachusetts, United States, 01655
United States, Michigan
Muskegon, Michigan, United States, 49444
Detroit, Michigan, United States, 48202
Detroit, Michigan, United States, 48201
United States, Minnesota
Rochester, Minnesota, United States, 55905
United States, Mississippi
Ocean Springs, Mississippi, United States, 39564
United States, Missouri
Everton, Missouri, United States, 65646
Kansas City, Missouri, United States, 64111
St. Louis, Missouri, United States, 63110
United States, Montana
Butte, Montana, United States, 59701
Missoula, Montana, United States, 59802
United States, New Hampshire
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Trenton, New Jersey, United States, 08629
Cedar Knolls, New Jersey, United States, 07927
Neptune, New Jersey, United States, 07753
Newark, New Jersey, United States, 07103
United States, New York
New Hyde Park, New York, United States, 11040
Albany, New York, United States, 12208
Syracuse, New York, United States, 13210
New York, New York, United States, 10016
United States, North Carolina
Greenville, North Carolina, United States, 27834
Raleigh, North Carolina, United States, 27612
Asheville, North Carolina, United States, 28801
United States, North Dakota
Fargo, North Dakota, United States, 58122
United States, Ohio
Akron, Ohio, United States, 44304
Toledo, Ohio, United States, 43608
Centerville, Ohio, United States, 45459
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19141
Lancaster, Pennsylvania, United States, 17602
Allentown, Pennsylvania, United States, 18102
Philadelphia, Pennsylvania, United States, 19140
Pittsburgh, Pennsylvania, United States, 15261
Pittsburgh, Pennsylvania, United States, 15212
Doylestown, Pennsylvania, United States, 18901
United States, South Carolina
Charleston, South Carolina, United States, 29401
Greenville, South Carolina, United States, 29605
United States, South Dakota
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Hermitage, Tennessee, United States, 37076
United States, Texas
Tyler, Texas, United States, 75702
Houston, Texas, United States, 77030
United States, Vermont
Burlington, Vermont, United States, 05403
United States, Virginia
Richmond, Virginia, United States, 23298
Danville, Virginia, United States, 24541
Richmond, Virginia, United States, 23249
Winchester, Virginia, United States, 22601
United States, Washington
Tacoma, Washington, United States, 98431
United States, Wisconsin
Marshfield, Wisconsin, United States, 54449
Milwaukee, Wisconsin, United States, 53226
Eau Claire, Wisconsin, United States, 54710
Canada, Alberta
Calgary, Alberta, Canada, T2N 2T9
Edmonton, Alberta, Canada, T5H 3V9
Canada, British Columbia
Victoria, British Columbia, Canada, V8R 1J8
Kelowna, British Columbia, Canada, V1V 1Y5
Kelowna, British Columbia, Canada, V1Y 1T2 & V1Y3G8
Vancouver, British Columbia, Canada, V5Z 3J5
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3A 1R9
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, New Brunswick
Moncton, New Brunswick, Canada, E1C 6Z8
Saint John, New Brunswick, Canada, E2K 4L2
Canada, Nova Scotia
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Windsor, Ontario, Canada, N8X 3V6
Ottawa, Ontario, Canada, K1H 8L6
Toronto, Ontario, Canada, M3N 2V6
Scarborough, Ontario, Canada, M1E 4B9
Toronto, Ontario, Canada, M5G 1X5
Toronto, Ontario, Canada, M2K 1E1
Ajax, Ontario, Canada, L1S 2J5
London, Ontario, Canada, N6A 4G5
Toronto, Ontario, Canada, M4N 3M5
Peterborough, Ontario, Canada, K9J 7B3
Windsor, Ontario, Canada, N9A 1E1
Toronto, Ontario, Canada, M5G 2M9 & M5G 1X5
Thunder Bay, Ontario, Canada, P7B 6V1
Hamilton, Ontario, Canada, L8N 4A6
Guelph, Ontario, Canada, N1E 4J4
Kingston, Ontario, Canada, K7L 3N6
Canada, Quebec
Chicoutimi, Quebec, Canada, G7H 5H6
Trois Rivieres, Quebec, Canada, G9A 1Y1
Montreal, Quebec, Canada, H3G 1A4
Levis, Quebec, Canada, G6V 3Z1
Quebec City, Quebec, Canada, G1L 3L5
Sainte Foy, Quebec, Canada, G1V 4G2
Montreal, Quebec, Canada, H1T 2M4
St-Hyacinthe, Quebec, Canada, J2S 4Y8
St. Charles Borromee, Quebec, Canada, J6E 2C3
Green Field Park, Quebec, Canada, J4V 2H1
Montreal, Quebec, Canada, H3A 1A1
Quebec City, Quebec, Canada, G1R 2J6
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada, S7K 1J5
Puerto Rico
San Juan, Puerto Rico, 00935
Sponsors and Collaborators
Genzyme
Investigators
Study Director: Medical Monitor Genzyme
  More Information

No publications provided

Responsible Party: Genzyme Corporation ( Medical Monitor )
Study ID Numbers: GD3-170-301
Study First Received: March 25, 2005
Last Updated: July 29, 2009
ClinicalTrials.gov Identifier: NCT00106509     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Genzyme:
Clostridium Enterocolitis
Pseudomembranous Colitis
Clostridium difficile-associated diarrhea
C. difficile
CDAD

Additional relevant MeSH terms:
Bacterial Infections
Anti-Infective Agents
Metronidazole
Antiprotozoal Agents
Diarrhea
Signs and Symptoms, Digestive
Gastrointestinal Diseases
Physiological Effects of Drugs
Colonic Diseases
Enterocolitis, Pseudomembranous
Intestinal Diseases
Enterocolitis
Pharmacologic Actions
Anti-Bacterial Agents
Signs and Symptoms
Antiparasitic Agents
Gram-Positive Bacterial Infections
Digestive System Diseases
Radiation-Sensitizing Agents
Therapeutic Uses
Vancomycin
Gastroenteritis
Clostridium Infections
Colitis

ClinicalTrials.gov processed this record on November 30, 2009